Bayer to Acquire Perfuse Therapeutics in $2.45B Deal

Why It Matters

The deal re‑energizes Bayer’s ophthalmology franchise and adds a late‑stage asset in two of the world’s largest eye‑disease markets, potentially boosting revenue and pipeline depth. It also signals a broader strategic shift as Bayer resumes aggressive M&A to offset slowing growth in its core businesses.

Key Takeaways

• Bayer commits $300M upfront, total potential $2.45B.
• PER‑001 targets glaucoma, diabetic retinopathy.
• Acquisition ends Bayer’s five‑year M&A pause.
• PER‑001 also being studied for dry AMD, vein occlusion.
• Bayer’s last drug deal was Vividion in 2021.

Pulse Analysis

Bayer’s return to drug‑centric acquisitions marks a pivotal shift after a near‑five‑year lull in M&A activity. The company’s recent strategic focus has been on cost‑cutting and divestitures, yet the competitive pressure in ophthalmology—driven by an aging population and rising prevalence of chronic eye diseases—has compelled it to seek external innovation. By securing Perfuse Therapeutics, Bayer not only adds a promising late‑stage candidate but also signals confidence in its ability to integrate biotech assets into a traditionally large‑molecule portfolio.

PER‑001, an intravitreal implant delivering a small‑molecule endothelin receptor blocker, tackles the vascular dysregulation that underlies glaucoma and diabetic retinopathy. These conditions together affect over 100 million patients globally, representing a multibillion‑dollar market. Existing therapies rely on daily eye drops or periodic injections, leaving room for sustained‑release platforms that improve adherence and outcomes. If PER‑001 progresses to registration, Bayer could capture a sizable share of a market where competitors like Novartis and Allergan are also expanding their pipeline.

Strategically, the acquisition bolsters Bayer’s ophthalmology franchise, which has lagged behind its oncology and crop‑science divisions. Integrating Perfuse’s technology may accelerate the development of additional indications such as dry age‑related macular degeneration and retinal vein occlusion, diversifying revenue streams. Moreover, the deal underscores a broader industry trend of large pharma leveraging biotech innovations to replenish pipelines. Bayer’s ability to move PER‑001 efficiently through regulatory milestones will be a litmus test for its renewed M&A vigor and its long‑term growth trajectory.

Deal Summary

Bayer announced it will acquire ophthalmology-focused biotech Perfuse Therapeutics, paying $300 million upfront with total consideration potentially reaching $2.45 billion based on milestones. The acquisition adds Perfuse’s PER‑001 intravitreal implant for glaucoma and diabetic retinopathy to Bayer’s pipeline. The deal, announced on May 6 2026, marks Bayer’s first drug‑focused acquisition in nearly five years.